LVIS™ EVO: Next-Generation Low-Profile Intraluminal Support Stent with Reduced Delivery Forces

The LVIS™ EVO is a next-generation braided nitinol intracranial stent from MicroVention Terumo, engineered as a refinement of the original LVIS and LVIS Jr platforms. Its defining improvement is a tighter correspondence between the delivery catheter working diameter and the deployed stent diameter — a characteristic the engineering team refers to as matched-profile deployment. This closer diameter match translates to more predictable deployment mechanics: the stent engages the vessel wall more smoothly and with less tendency to jump proximally during the final moments of sheath retraction, giving the operator greater control over landing zone accuracy.

The EVO also achieves substantially lower delivery and resheathing forces than the standard LVIS, which is meaningful in daily practice because it reduces the push force needed to advance the delivery system through tortuous access routes and reduces the pull force needed to resheath the device for repositioning. Operators transitioning from standard LVIS to EVO consistently describe the deployment as feeling lighter and more controlled.

The LVIS EVO covers parent artery diameters from 2.5 mm to 4.0 mm in lengths from 12 mm to 31 mm. The catalog spans LEV2512 (2.5 mm deployed diameter, 12 mm length) through LEV4031 (4.0 mm, 31 mm). The device is delivered via Headway 17 microcatheter for the 2.5–3.0 mm sizes and via Headway 21 for the 3.0–4.0 mm range, over a standard 0.014 in guidewire. The braided nitinol construct provides approximately 23% metal surface area coverage.

The EVO uses the same electrolytic detachment system as the standard LVIS, and all LVIS procedural accessories are compatible. Radiopaque markers at both ends of the stent body provide fluoroscopic position references during deployment.

LVIS Jr (Headway 17, vessels ≥2.0 mm) and LVIS (Headway 21, 2.5–5.5 mm) represent the established generation with long clinical track records. The EVO occupies the 2.5–4.0 mm range with reduced delivery forces — its primary advantage over LVIS in cases with tortuous cervical or intracranial access. For straightforward anatomy where LVIS delivery has never been difficult, the choice between LVIS and LVIS EVO is primarily one of program preference and inventory standardisation.

Programs adopting neurointerventional services for the first time may prefer to standardise on the LVIS EVO as their single intracranial stent platform across the 2.5–4.0 mm range, rather than stocking both LVIS and LVIS Jr. The EVO’s matched-profile design and improved delivery mechanics make it the better choice for high-difficulty cases, and its single-device simplicity reduces inventory complexity.

LVIS EVO is indicated for stent-assisted coil embolization of wide-neck intracranial aneurysms where the neck-to-parent-artery diameter ratio or dome-to-neck ratio makes primary coiling technically unstable. DAPT with aspirin and clopidogrel must be loaded ≥5 days before the procedure and continued per institutional protocol post-implant.

The EVO’s tortuous-access performance makes it particularly appropriate for posterior circulation cases accessed via a tortuous vertebral artery, and for anterior circulation cases with pronounced carotid siphon angulation. Programs that have experienced LVIS delivery failures in difficult anatomy should trial the EVO as the first-line device for future difficult-access cases.

Modern Medical Solutions is the authorised MicroVention Terumo distributor for Tajikistan and Afghanistan. LVIS EVO is available across the full LEV2512 through LEV4031 catalog for neurointerventional programmes in Tajikistan and Afghanistan.

Contact Modern Medical Solutions to discuss LVIS EVO alongside standard LVIS, LVIS Jr, and Headway 17/21 microcatheters as a complete stent-assisted coiling system.